Clinical Study of Smoke-Break Liquid Cigarettes

NCT ID: NCT00715871

Last Updated: 2014-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the Smoke-Break nicotine delivery device can help smokers quit smoking, while avoiding many of the side effects associated with other smoking cessation products.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has been completed and published. The published study manuscript can be found here: http://www.biomedcentral.com/1471-2458/10/155

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Smokers

Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.

Group Type EXPERIMENTAL

Nicotine

Intervention Type DRUG

Subjects received an amount of "liquid nicotine cigarettes" (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of "liquid nicotine cigarettes" received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study.

Smoke-Break nicotine delivery device

Intervention Type DEVICE

The Smoke-Break nicotine delivery device is a "liquid nicotine cigarette" designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotine

Subjects received an amount of "liquid nicotine cigarettes" (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of "liquid nicotine cigarettes" received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study.

Intervention Type DRUG

Smoke-Break nicotine delivery device

The Smoke-Break nicotine delivery device is a "liquid nicotine cigarette" designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Smoke-Break, liquid cigarette, liquid nicotine cigarette Smoke-Break, liquid cigarette, liquid nicotine cigarette

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteer is at least 18 years of age.
* Volunteer currently smokes cigarettes, cigars or other forms of tobacco products for at least one year.
* Volunteer wants to quit smoking.
* Volunteer will be fully informed as to the nature of the study.
* Volunteer will have no known allergy to any product ingredients as listed in the informed consent.
* Volunteer agrees to a confidential pretest questionnaire and periodic monitoring as to the effectiveness of the smoking cessation regimen.
* Volunteers are not currently using another nicotine replacement therapy.
* Volunteer will agree to use birth control measures while on the study.

Exclusion Criteria

* Volunteer has a known allergy or hypersensitivity to nicotine or other related ingredients as outlined in the informed consent.
* Volunteer does not desire to quit smoking.
* Volunteer is using another nicotine replacement therapy.
* Volunteer is pregnant or breast-feeding.
* Volunteer has a history of heart disease or advanced diabetes.
* Volunteer indicates on the application that they smoke ten (10) or fewer cigarettes per day.
* Volunteer is using a daily prescription medicine for depression or asthma.
* Volunteer is using a non-nicotine smoke cessation drug, such as Zyban or Chantix.
* Volunteer is an employee of Smoke-Break Inc., or is personally known to an employee of Smoke-Break Inc.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smoke-Break, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicholas Geimer, MD

Role: PRINCIPAL_INVESTIGATOR

Smoke-Break, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tommy G. Thompson Youth Center

West Allis, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Geimer N, Olson CE, Baumgarten D, Kepner JL, Mahoney MC. Use of a liquid nicotine delivery product to promote smoking cessation. BMC Public Health. 2010 Mar 24;10:155. doi: 10.1186/1471-2458-10-155.

Reference Type DERIVED
PMID: 20334673 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SB07211

Identifier Type: -

Identifier Source: org_study_id